XENETIC BIOSCIENCES, INC. Increase (Decrease) in Prepaid Expense and Other Assets
XENETIC BIOSCIENCES, INC. (XBIO) reported Increase (Decrease) in Prepaid Expense and Other Assets of $16.02 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- XENETIC BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$65.50K, a 125.17% decline year-over-year.
- XENETIC BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $81.52K.
- XENETIC BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was $260.23K.
- XENETIC BIOSCIENCES, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-03-31 was -$108.33K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month |
|---|---|---|---|
| 2026-06-30 | -$65.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.02K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $81.52K 10-Q · filed 2026-05-12 | ||
| 2025-06-30 | $260.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $151.90K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | -$108.33K 10-Q · filed 2026-05-12 | ||
| 2019-09-30 | -$477.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$238.99K derived: sum of 2 quarters · filed 2019-11-14 | $297.71K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $238.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $775.26K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $536.70K 10-Q · filed 2019-05-13 | ||
| 2018-09-30 | -$69.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $258.35K derived: sum of 2 quarters · filed 2019-11-14 | $310.24K 10-Q · filed 2019-11-14 |
| 2018-06-30 | $327.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $379.88K 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $51.89K 10-Q · filed 2019-05-13 | ||
| 2017-09-30 | -$198.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$597.82K derived: sum of 2 quarters · filed 2018-11-09 | -$13.27K 10-Q · filed 2018-11-09 |
| 2017-06-30 | -$399.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $185.54K 10-Q · filed 2018-08-10 | |
| 2017-03-31 | $584.56K 10-Q · filed 2018-05-15 | ||
| 2016-09-30 | -$6.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$87.61K derived: sum of 2 quarters · filed 2017-11-14 | -$43.68K 10-Q · filed 2017-11-14 |
| 2016-06-30 | -$80.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$36.99K 10-Q · filed 2017-08-14 | |
| 2016-03-31 | $43.93K 10-Q · filed 2017-05-15 | ||
| 2015-09-30 | -$50.46K 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |